Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR …
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
[HTML][HTML] Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
NCP Cross, HE White, D Colomer, H Ehrencrona… - Leukemia, 2015 - nature.com
Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …
advanced to a stage where many patients achieve very low or undetectable levels of …
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
[HTML][HTML] Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors
(TKIs), especially in the absence of kinase domain mutations in BCR-ABL1, is poorly …
(TKIs), especially in the absence of kinase domain mutations in BCR-ABL1, is poorly …
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response …
S Branford, L Fletcher, NCP Cross… - Blood, The Journal …, 2008 - ashpublications.org
An international basis for comparison of BCR-ABL mRNA levels is required for the common
interpretation of data derived from individual laboratories. This will aid clinical decisions for …
interpretation of data derived from individual laboratories. This will aid clinical decisions for …
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA …
Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
[HTML][HTML] Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
NP Shah, BJ Skaggs, S Branford… - The Journal of …, 2007 - Am Soc Clin Investig
Molecularly targeted kinase inhibitor cancer therapies are currently administered
sequentially rather than simultaneously. We addressed the potential long-term impact of this …
sequentially rather than simultaneously. We addressed the potential long-term impact of this …
[HTML][HTML] Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
MM Sampaio, MLC Santos, HS Marques… - World journal of …, 2021 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
[HTML][HTML] European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
NCP Cross, T Ernst, S Branford, JM Cayuela… - Leukemia, 2023 - nature.com
From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …